RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS

Patients with lower-risk myelodysplastic syndromes (LR-MDS) have a generally favorable prognosis; however, a small proportion of cases progress rapidly. This study aimed to define molecular biomarkers predictive of LR-MDS progression and to uncover cellular pathways contributing to malignant transfo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaisrlikova, Monika, Vesela, Jitka, Kundrat, David, Votavova, Hana, Dostalova Merkerova, Michaela, Krejcik, Zdenek, Divoky, Vladimir, Jedlicka, Marek, Fric, Jan, Klema, Jiri, Mikulenkova, Dana, Stastna Markova, Marketa, Lauermannova, Marie, Mertova, Jolana, Soukupova Maaloufova, Jacqueline, Jonasova, Anna, Cermak, Jaroslav, Belickova, Monika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252911/
https://www.ncbi.nlm.nih.gov/pubmed/35505182
http://dx.doi.org/10.1038/s41375-022-01584-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252911/
https://www.ncbi.nlm.nih.gov/pubmed/35505182
http://dx.doi.org/10.1038/s41375-022-01584-3

Ejemplares similares